Workflow HPLC-Chip for Biopharmaceutical Analysis

Agilent Technologies, Inc has introduced a new HPLC-Chip to address N-glycan analysis in the emerging biopharmaceutical market.

The mAb-Glyco-Chip is designed for the analysis of N-glycans associated with monoclonal antibody molecules. N-glycans and monoclonal antibody molecules are a critical part of biopharmaceutical research and analysis. A unique product for a specific requirement, the mAb-Glyco-Chip improves the productivity of biopharmaceutical analysis at least 20 times when compared to the current CE-FLD method, and at least five times
when compared to the current MALDI-MS method.

Conventional methods of N-glycan analysis, such as LC-FLD or CE-FLD, can take two to three days for completing one single analysis. The new HPLCChip/ MS workflow significantly reduces the total analysis (including on-chip enzymatic reaction, glycan separation and MS analysis) to tens of minutes. This creates a major productivity enhancement for biopharmaceutical analysis. Coupled with an Agilent Accurate Mass TOF or QTOF
mass spectrometer, the combined system allows for complete, rapid characterisation and quantitative profiling of glycan structures on recombinant antibodies.

The Agilent 1200 Series HPLC-Chip/MS system is a microfluidic chip-based technology for nanospray LC/MS. Agilent pioneered the HPLC-Chip/MS concept in 2005, combining nanoflow HPLC columns, and connecting capillaries and a spray emitter, into a re-useable, credit card-size device. This allowed the advantages of high-sensitivity and low-sample consumption provided by nano LC/MS to be accessible to scientists without the
troublesome setup involving microvalve, fittings and capillary tubing of conventional nano LC.

The mAb-Glyco-Chip will be available in September.